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Abstract
Introduction: Repeat HIV testing during the late antenatal period is crucial to identify and initiate treatment for pregnant
women with incident HIV infection to prevent perinatal HIV transmission and keep mothers alive. In 2012, the Kenya Ministry
of Health adopted international guidelines suggesting that pregnant women be offered retesting three months after an initial
negative HIV test. Our objectives were to determine the current rate of antenatal repeat HIV testing; identify successes,
missed opportunities and factors associated with retesting; and estimate the incidence of HIV during pregnancy.
Methods: Retrospective analysis of longitudinal data was conducted for a cohort of 2145 women attending antenatal care
clinic at a large district hospital in southwestern Kenya. Data were abstracted from registers for all women who attended the
clinic from the years 2011 to 2014.
Results: Although 90.2% of women first came to clinic prior to their third trimester and 27.5% had at least four clinic visits,
58.0% of all women went to delivery without a retest. Missed opportunities for retesting included not returning to clinic at all,
not returning when eligible, or late gestational age (>28 weeks) at first clinic visit making them ineligible for retesting (ac-
counting for 14.2%, 26.8% and 9.6% of all clinic attendees respectively); and failure to be retested even when eligible at one
or more visits (accounting for 73.2% of eligible returnees). Being unmarried and aged 20 or younger was associated with an
increase in mean gestational age of first visit by 2.52 weeks (95% CI: 1.56, 3.48) and a 2.59 increased odds (95% CI: 1.90,
3.54) of failing to return to clinic, compared to those who were married and over 20 years of age. On retest, two women
tested HIV positive, suggesting an incidence rate of 4.4 per 100 person-years. After adjusting for potential confounders, only
later year of last menstrual period (2013 vs. 2012 and 2011) was associated with retesting.
Conclusions: Adoption of retesting guidelines in 2012 appears to have successfully increased retesting rates, but missed
opportunities to identify incident HIV infection during pregnancy may contribute to continuing high rates of perinatal HIV
transmission in southwestern Kenya.
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1 | INTRODUCTION
Pregnant women with chronic HIV infection are increasingly
identified as seropositive and being placed on antiretroviral
treatment (ART) at first antenatal care (ANC) visit due to
the expansion of HIV testing into ANC settings and the
adoption of policies suggesting immediate and lifelong initia-
tion of ART for pregnant women (“Option B+”) [1,2]. Thus,
pregnant women who initially test HIV negative in ANC and
then subsequently experience HIV seroconversion during the
perinatal period are likely to be contributing to a growing
proportion of mother-to-child transmission (MTCT) events
[3]. This is particularly true because acute HIV infection is
associated with elevated viral loads that increase risk of
transmission during pregnancy, delivery and through breast-
feeding [4,5].
Repeat HIV testing during pregnancy allows women who
have seroconverted since first antenatal test to be aware of
their HIV status and initiate ART for their own sake, as well
as to prevent MTCT [2]. Infants born to mothers of known
HIV-positive status are often more closely followed as HIV-
exposed infants: they are given HIV prophylaxis at delivery
and for a period of time after birth, tested through early
infant diagnosis programmes, and immediately initiated on
ART if found to be infected with HIV [6,7].
In Kenya, there are roughly 1.5 million pregnancies and
87,000 HIV-positive pregnant women per annum [8]. The
MTCT rate was estimated in 2012 to be 15%, accounting for
13,000 new childhood infections in Kenya annually [9,10]. In
2012, the Kenya Ministry of Health adopted international
guidelines recommending that repeat HIV testing be offered
three months after an initial negative HIV test result in early
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pregnancy [11]. While one study in Kenya found the accept-
ability of provider-initiated retesting in late pregnancy to be
93.5% [12], only one known study from Zambia has reported
the retesting rate in a non-intervention setting to be 24.5%
among eligible pregnant women [13]. In addition, little is
known about gaps in implementation of repeat HIV testing
and the factors associated with a lack of retesting, thus mak-
ing it challenging to address the deficits.
The purpose of this paper was to determine the current
rate of antenatal repeat HIV testing; identify successes,
missed opportunities and factors associated with retesting;
and estimate the incidence of HIV during pregnancy at a large
hospital in southwestern Kenya.
2 | METHODS
2.1 | Setting and Context
This study was conducted at a large government hospital in
rural southwestern Kenya, an area of the country with the
highest HIV prevalence at 15.1% [14]. The facility is one of
three district hospitals in the county and has a large patient
volume comprising of primarily low-income clients. The Kenya
AIDS Indicator Survey 2012 found that for Kenya overall,
95.4% of reproductive-aged women attended ANC clinic dur-
ing pregnancy, 93.1% of whom were tested for HIV at least
once during their last pregnancy [15]. In the study setting, the
Kenya Ministry of Health facility was supported by Family
AIDS Care and Education Services (FACES), a PEPFAR-funded
programme that provides integrated HIV and ANC care [16].
2.2 | Study Design
In early 2015, longitudinal antenatal record data for the full
pregnancy were abstracted from paper ANC registers for all
women attending the antenatal clinic of the hospital in the
years 2011 to 2014. Data for pregnant women were excluded
if they had their last menstrual period (LMP) in the year
2014, since these women may not have records for their
entire pregnancy included in the dataset, or if their first ante-
natal visit was at a different clinic, since it would constitute
missing information on gestational age at first ANC visit and
HIV test result. Ethical approval was given by the Kenya Med-
ical Research Institute Scientific and Ethical Review Unit
(SERU) and the University of Alabama at Birmingham Institu-
tional Review Board. As the data were gathered as a part of
routine medical care and de-identified after linkage, individual
patient consent was not solicited as a part of this study.
2.3 | Variable Definitions
Women were coded as having had an initial HIV test if their
records noted that they tested HIV-negative or -positive on
their first ANC clinic visit, and they were not an individual
with a “known HIV-positive” status at the start of the visit.
Women were eligible for a repeat HIV test if they visited the
ANC clinic again at least 12 weeks after their initial visit with
an HIV-negative test result. Women were coded as having
been retested if records indicated an HIV-negative or -positive
test on an eligible re-visit; otherwise a missed opportunity
was noted accordingly. Women were ineligible for a retest if
they had previously tested positive for HIV or if they did not
come early enough for their first clinic visit (i.e. ≤28 weeks
gestational age) to have another HIV test during the current
pregnancy, as per national guidelines.
Seroconversion during pregnancy was defined as having an
HIV-negative result at the initial HIV test, and an HIV-positive
result on retest at least 12 weeks later. Village distance from
the hospital was estimated by utilizing the expertise of local
facility transport staff, who deliver supplies such as medicines
and biological specimens between government health facilities,
to determine the distance between women’s village locations
as listed in the ANC register and the hospital. Pregnancy
cohorts were defined by the year of their LMP.
2.4 | Data Analysis
Data that had been entered into an electronic database were
cleaned and analysed in SAS Version 9.4 (SAS Institute Inc.,
Cary, NC, USA). Bivariate and multivariable analyses were con-
ducted using linear and logistic regression, along with linear
trend analyses, to assess the statistical association of patient
demographic variables with process measures, including gesta-
tional age at first visit and returning to antenatal clinic, as well
as outcome measures, such as getting a repeat HIV test [17].
Specifically, to understand the characteristics of women who
received repeat HIV testing as compared to those who did not,
we ran a series of analyses with the dependent variables (A)
gestational age at first visit, which impacts whether or not a
woman will become eligible for repeat HIV testing, (B) whether
or not the woman returned to clinic, which impacts being
offered a repeat HIV test and (C) whether or not the woman
received a retest. Both bivariate and multivariable models were
presented since the unadjusted models provide information on
the target population for implementation of strategies, while
the adjusted models account for confounding to better describe
what factors drive the trends.
3 | RESULTS
3.1 | Characteristics of the Study Population
A total of 2160 women who had an LMP in the years 2011,
2012 and 2013 attended antenatal clinic at the study facility.
Ninety-six women had two pregnancies fall within the time
span of data collected; all women were kept in the sample but
only the first pregnancy was included in analyses. We excluded
15 women from the dataset for having their first antenatal
visit at a different clinic, leaving us with a sample of 2145
(Table 1). Of the 2145 women remaining in the sample, the
mean age was 23.5 years (standard deviation (SD) 5.48) with
a mean estimated village distance from clinic of 4.7 km (SD
6.45), with a minority of 5% living over 15 km away. Fifteen
per cent of the women were either single or no longer in a
marital relationship, 28.4% of all women had four or more
children, and most women (80.1%) came for their first ANC
visit during the second trimester, with a mean gestational age
of 21.6 weeks (SD 6.3). Just over a quarter (27.5%) of all
women had at least the four recommended ANC visits (30.0%
when considering only women who came prior to their third
trimester; and 54.7% when considering only women who had
an initial visit during their first trimester).
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Nineteen per cent of the women already knew of their
HIV-positive status prior to their first ANC visit, while another
6.7% were diagnosed as being HIV positive for the first time
at their first ANC visit of the current pregnancy. At delivery,
14.0% were considered to be known HIV negative, having had
their most recent HIV test within the last three months, and
58.0% of all women went to delivery without a repeat HIV
test despite having last tested HIV negative more than three
months prior. Overall acceptance of the HIV test during preg-
nancy was very high at 98.0%.
3.2 | Characterizing Missed Opportunities
Of all women in our sample, 207/2145 (9.6%) presented after
28 weeks gestational age for their first antenatal visit, making
them ineligible for repeat HIV testing later in pregnancy or at
delivery (Figure 1). Among these women, 7/207 (3.4%) tested
HIV positive for the first time, possibly constituting a missed
opportunity for early maternal ART initiation to suppress viral
load and prevent MTCT.
The majority of women (1938/2145, 90.4%) initially pre-
sented to ANC by 28 weeks gestational age. Of those, 392/
1938 (20.2%) were known HIV positive, 136/1938 (7.0%)
were newly HIV positive, and 35/1938 (1.8%) had missing test
results, leaving 1375/1938 (71.0%) women who tested HIV
negative eventually eligible for a retest later in pregnancy. Of
these eligible women, 305/1375 (22.2%) never returned to
the ANC clinic and 576/1070 (53.8%) returned to clinic but
not on a date at which they were eligible for retesting, since
they came before 12 weeks had passed. Of the 494/1070
(46.2%) who returned when eligible, 132/494 (26.8%) were
eventually retested, while 362/494 (73.2%) were not retested,
even though eligible at one or more visits. Of the total of
1375 women who should have had a repeat HIV test later in
pregnancy, only 132 (9.6%) were retested.
Thus, missed opportunities to retest the target population
of 1375 potentially eligible women included (A) women who
did not return to clinic at all, (B) women who did not have vis-
its spaced out in such a way that they were eligible when they
did return, and (C) women who were not retested, although
eligible at one or more ANC visits.
3.3 | Characterizing factors associated with process
and outcome measures
3.3.1 | Factors associated with early gestational age
at first visit
Having a first ANC visit early in pregnancy impacts eligibility for
HIV retesting (as per the 28 weeks gestational age threshold)
and allows for more time to fit in the four ANC visits recom-
mended by the Ministry of Health. In bivariate analyses, known
HIV-positive status prior to first visit was significantly associ-
ated with earlier gestational age at first visit when compared
with being HIV negative or newly diagnosed as HIV positive
(Table 2). Later year of pregnancy and older age were similarly
associated with earlier gestational age at first visit, a trend that
held true even when we dichotomized the gestational age to
being less than/equal to or greater than 28 weeks at first ANC
visit (data not shown). Conversely, being unmarried or previ-
ously married (widowed, divorced, or separated) was associated
with later average gestational age at first visit when compared
with being married. In multivariable analyses, after adjusting for
the effect of HIV status at first visit, marital status, year of preg-
nancy, and village distance from clinic, older age was no longer a
significant predictor of gestational age at first visit.
Unexpectedly, in bivariate analyses, women who lived at a
greater distance from the clinic came, on average, earlier than
women who lived closer to the clinic. To assess this finding, we
ran an analysis and determined that being of known HIV-posi-
tive status and older age correlated with living further away, but
marital status did not (data not shown). In multivariable
Table 1. Descriptive characteristics of the study sample
(N = 2145)
Variable Mean (SD) n (%)
Age (years) 23.5 (5.48)
Estimated village distance
from hospital (km)
4.7 (6.45)
Gestational at first
ANC visit (weeks)
21.6 (6.3)
Year of pregnancy
2011 519 (24.2)
2012 738 (34.4)
2013 888 (41.4)
Number of ANC visits
1 501 (23.4)
2 509 (23.7)
3 545 (25.4)
≥4 590 (27.5)
Marital status
Married 1785 (83.3)
Single 225 (10.4)
Widowed/Divorced/Separated 99 (4.6)
Missing 36 (1.7)
Gravida
Primigravid 602 (28.0)
2 530 (24.7)
3 401 (18.9)
4 289 (13.5)
5 182 (8.5)
≥6 141 (6.4)
Gestational age at first ANC visit
≤12 weeks 221 (10.3)
13 to 20 weeks 731 (34.1)
21 to 28 weeks 986 (46.0)
29 to 36 weeks 203 (9.5)
≥37 weeks 4 (0.1)
HIV status at delivery
Known HIV positive at first visit 413 (19.3)
Newly diagnosed HIV positive in ANC 143 (6.7)
Negative 300 (14.0)
Previously negativea 1245 (58.0)
Not done/Missing 44 (2.0)
ANC, antenatal care.
aDefined as having had more than three months pass since the last
HIV-negative test result.
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analyses, after adjusting for both HIV status and age, character-
istics that are significant predictors of gestational age of first
visit, travelling a greater distance to clinic was no longer associ-
ated with earlier gestational age at first visit (Table 2).
Sensitivity analyses excluding the small population who lived
far away from the clinic (operationalised as the 5% of the pop-
ulation who lived in a village ≥15 km away and who appeared
to have different characteristics than other clients) did not
qualitatively change the reported results.
3.3.2 | Factors associated with returning to clinic
Returning to clinic is a prerequisite for getting retested for
HIV. Having a first ANC visit by 28 weeks gestational age
was associated with 3.75 times the odds (95% CI: 2.79, 5.05)
of returning to clinic over having a first ANC visit between 29
to 36 weeks. In bivariate analyses, known HIV-positive status
prior to first visit was associated with 2.38 times the odds
(95% CI: 1.69, 3.14) of returning to clinic compared with
being HIV negative (Table 2).
In multivariable analyses, women who were of known HIV-
positive status, were married, and/or were age 31 and older
were significantly more likely to return to clinic. Being diag-
nosed with HIV during pregnancy was also a risk factor for
failing to return to antenatal clinic, as newly positive women
had a 0.62 odds (95% CI: 0.42, 0.92) of returning to clinic
compared to those who tested negative in pregnancy even
after adjusting for potential confounders. This is in contrast to
women who knew their HIV-positive status prior to initiating
ANC and who had significantly increased odds of returning to
clinic. Being unmarried and aged 20 or younger was associ-
ated with an increase in mean gestational age of first visit by
2.52 weeks (95% CI: 1.56, 3.48) and a 2.59 odds (95% CI:
1.90, 3.54) of failing to return to clinic, compared to those
who were married and over 20 years of age.
3.3.3 | Factors associated with getting retested for HIV
In our target population, all the women who came early
enough to be eligible for retesting (n = 1375), we assessed
Figure 1. Missed opportunities for repeat HIV testing and early antiretroviral therapy initiation at a district hospital in southwestern Kenya,
2011 to 2014. Dark black boxes indicate missed opportunities for repeat HIV testing (among women whose first antenatal care (ANC) visit
was at ≤28 weeks gestational age) or early intervention of mother-to-child transmission of HIV through initiating antiretroviral therapy
(among women whose first ANC visit was >28 weeks gestational age). Among patients who returned when eligible for a repeat HIV test
(n = 494), “number of missed opportunities” indicates the number of times that they came for a clinic visit when eligible for a repeat HIV
test, but were not tested. Thus, among eligible returnees who were eventually retested (n = 132), some had come for one or two visits
when eligible without getting a retest. Similarly, among eligible returnees who were never retested (n = 362), they may have come to ANC
anywhere between one and five times when eligible without getting a retest. Percentages are a subset of the level right above.
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the relationship between patient characteristics and retesting.
In bivariate analyses, we found that only marital status and
year of pregnancy were significantly associated with getting
retested (Table 3).
When considering the subset of eligible women who did
return to clinic (n = 494), we found that only year of preg-
nancy was associated with getting retested. Using a multivari-
able Poisson regression model to examine the factors
associated with having multiple missed opportunities for
retesting yielded a similar result. Of these 494 women, we
found that in 2011, only 1 of 105 eligible patients was
retested (0.95%); in 2012, 31 of 162 eligible patients were
retested (19.14%) and in 2013, 100 of 227 (44.05%) eligible
patients were retested.
The results of bivariate analyses from Tables 2 and 3
are summarized in Figure 2 to highlight the target
population for implementation of strategies. The presence of
an arrow indicates a statistically significant positive
association.
3.4 | Outcomes of repeat HIV testing
The 132 women who were retested contributed a mean of
125 days (range = 83 to 196 days) between initial HIV test
and retest, for a total of 45.4 person-years. Two women sero-
converted from being HIV negative at initial test to being HIV
positive on retest, corresponding to a (2/132) 1.5% cumulative
incidence and an incidence rate of (100/45.492) 4.4 per
100 person-years. Extrapolating the incidence rates to our
target population would suggest that had we retested all
potentially eligible women (n = 1375), we may have identified
an additional 18 women who had seroconverted by delivery.
Table 2. Factors affecting gestational age at first visit and return to clinic
Gestational age at first visit (weeks) Returned to clinic at least once
Bivariate analyses Multivariable analyses Bivariate analyses Multivariable analyses
Factor N
Mean gestational
age (SD) p-value b (SE) p-value OR (95% CI) p-value aOR (95% CI) p-value
HIV status at first visit
Negative 1545 22.4 (6.0) <0.0001 Ref. <0.0001 Ref. <0.0001 Ref. <0.001
Newly positive 143 21.4 (5.7) 0.80 (0.55) 0.74 (0.51, 1.07) 0.62 (0.42, 0.92)
Known positive 413 18.6 (6.5) 3.60 (0.36) 2.38 (1.69, 3.14) 1.85 (1.32, 2.58)
Marital status
Married 1785 21.3 (6.4) <0.0001 Ref. <0.0001 Ref. <0.0001 Ref. <0.001
Prev. married 99 22.7 (5.3) 0.70 (0.66) 0.55 (0.35, 0.85) 0.56 (0.35, 0.90)
Unmarried 225 23.8 (5.5) 2.07 (0.47) 0.38 (0.29, 0.52) 0.49 (0.35, 0.69)
LMP yearb
2011 519 22.3 (5.9) <0.05 Ref. <0.05 Ref. <0.05 Ref. 0.159
2012 738 21.7 (6.3) 0.81 (0.36) 0.92 (0.70, 1.22) 0.92 (0.68, 1.23)
2013 888 21.2 (6.4) 1.29 (0.35) 0.74 (0.57, 0.96) 0.77 (0.58, 1.02)
Age of patientb
≤15 years 124 23.4 (6.0) <0.0001 Ref. 0.437 Ref. <0.0001 Ref. 0.052
16 to 20 years 649 22.4 (5.9) 0.49 (0.63) 1.18 (0.78, 1.78) 1.06 (0.68, 1.65)
21 to 30 years 1147 21.2 (6.4) 0.28 (0.63) 1.89 (1.27, 2.8) 1.33 (0.84, 2.10)
≥31 years 225 20.8 (6.8) 0.04 (0.75) 2.97 (1.75, 5.05) 1.87 (1.04, 3.39)
Village distance from clinicb
≤5 km 1598 21.7 (6.3) <0.05 Ref 0.150 Ref. 0.768 Ref. 0.714
6 to 15 km 334 21.9 (6.1) 0.52 (0.37) 1.09 (0.82, 1.45) 1.07 (0.79, 1.44)
16 to 30 km 93 18.8 (6.3) 1.55 (0.66) 0.99 (0.60, 1.61) 0.78 (0.46, 1.34)
≥31 km 21 18.1 (5.4) 2.36 (1.34) 0.98 (0.35, 2.69) 0.74 (0.26, 2.12)
Paritya,b
Primigravid 602 21.5 (6.0) 0.441 N/A N/A Ref. <0.0001 N/A N/A
2 530 21.7 (6.4) N/A 1.4 (1.07, 1.84) N/A
3 401 21.2 (6.5) N/A 1.59 (1.18, 2.15) N/A
4 608 21.9 (6.2) N/A 1.74 (1.33, 2.28) N/A
CI, Confidence interval; SD, standard deviation; SE, standard error; b, regression beta coefficient; LMP, last menstrual period; Prev., previously; N/
A, not applicable; OR, odds ratio; aOR, adjusted odds ratio; Ref., reference.
aMultivariable analyses controlled for all other variables in the table except for parity because of its collinearity with age.
bReported p-values are for trend.
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4 | DISCUSSION
Repeat HIV testing and early ART initiation are important
components of ANC in settings of high HIV incidence. Utilizing
routinely collected antenatal record data from a large hospital
in southwestern Kenya, our study found that the dissemina-
tion and implementation of guidelines for repeat HIV testing,
which occurred in 2012, were successful in making a consider-
able impact on rates of repeat HIV testing through encourag-
ing provider-initiated rather than patient-initiated requests for
retesting. Specifically, guideline dissemination was associated
with an increase in retesting from less than 1% among women
with LMPs in 2011 to nearly 45% among women with LMPs
in 2013. However, missed opportunities continue to exist for
both repeat HIV testing and early ART initiation, leading to
potential MTCT of HIV that may have otherwise been inter-
vened upon.
Key missed opportunities included later gestational age at
first ANC visit, leading to potentially delayed initial identifica-
tion of HIV seropositivity and linkage to HIV care, failing to
return to antenatal clinic after an initial visit, and failing to get
retested even though eligible. Conversely, earlier gestational
age was positively associated with returning to clinic, which
was in turn a prerequisite for getting retested for HIV.
Table 3. Factors associated with getting retested for HIV (bivariate analyses)
Factor
Retested for HIV among target population
(n = 1375)
Retested for HIV among eligible women who
returned to clinic (n = 494)
N Odds Ratio (95% CI) p-value N Odds Ratio (95% CI) p-value
Marital status
Married 1113 Ref. 0.038 425 Ref. 0.73
Unmarried or previously married 237 0.54 (0.30, 0.96) 56 0.89 (0.47, 1.7)
LMP year
2011 316 Ref. <0.0001 105 Ref. <0.0001
2012 466 22.2 (3.01, 163) 162 24.3 (3.27, 181)
2013 593 63.4 (8.80, 456) 227 81.0 (11.1, 591)
Age of patient
≤15 years 89 Ref. 0.17 21 Ref. 0.52
16 –20 years 479 2.21 (0.77, 6.33) 157 0.99 (0.23, 3.84)
21–30 years 711 2.58 (0.92, 7.24) 283 1.72 (0.54, 5.40)
≥31 years 96 1.41 (0.38, 5.19) 33 1.58 (0.51, 4.87)
Parity
Primigravid 479 Ref. 0.77 21 Ref. 0.91
2 346 1.09 (0.69, 1.73) 157 0.97 (0.58, 1.60)
3 247 0.93 (0.55, 1.58) 283 0.97 (9.54, 1.75)
4 301 0.83 (0.50, 1.38) 33 0.82 (0.46, 1.44)
Village distance from clinic
≤15 km 1264 Ref. 0.17 457 Ref. 0.11
>15 km 50 0.37 (0.09, 1.5) 19 0.30 (0.70, 1.35)
CI, Confidence interval; LMP, last menstrual period; Ref., reference; km, kilometers
Figure 2. Factors associated with earlier gestational age at first visit, returning to clinic, and getting retested for HIV (bivariate analyses).
Arrows indicate a statistically significant positive association between pregnant women’s characteristics and process measures (earlier gesta-
tion at first visit and return to clinic) as well as the outcome measure (getting retested for HIV).
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Factors contributing to earlier gestational age at first visit
included known HIV-positive status prior to first visit, being
married, and being of older age. Similar factors contributed to
likelihood of returning to clinic. Thus, all these demographic
characteristics may have influenced likelihood of getting
retested for HIV.
We found that initial HIV testing rates (98.0%) in our
study were higher than the national average (93.1%), poten-
tially due to a higher HIV prevalence in the region [9]. In a
recent meta-analysis, Drake et al. reported the pooled cumu-
lative incidence of HIV during pregnancy to be 1.5% (95%
CI 1.2% to 1.8%), although African countries had a higher
rate when compared to non-African countries (3.6% vs. 0.3%,
respectively, p < 0.001) [18]. They also reported a pooled
incidence rate of 4.7 (95% CI 3.3 to 6.1) per 100 person-
years [18]. Kinuthia et al. reported in 2010 data from the
Nairobi and Nyanza regions of Kenya supporting a cumula-
tive incidence 2.6% and an incidence rate of 6.8 per
100 person-years [12]. The cumulative incidence rate of
1.5% and incidence rate of 4.4 per 100 person-years
reported in this study thus correspond closely to the rates
reported in the literature. Our incidence rates should be
interpreted in the light of the fact that they were estimated
among women who returned to ANC when eligible and
received a retest, a group that may have a different risk pro-
file for HIV acquisition during pregnancy than women who
did not return to ANC or who were not retested for other
reasons. We also found that known HIV-positive status prior
to first visit was significantly associated with earlier gesta-
tional age at first visit and returning to clinic, possibly
because this group is already engaged in HIV care services
at the facility, is used to accessing care, or have been
encouraged by HIV providers to access ANC early to pre-
vent MTCT.
Several themes relevant to improving the implementation of
repeat HIV testing guidelines emerged from the data. At the
patient level, various types of stigmas may have influenced
ANC choices. For women who were young and/or unmarried,
as well as women who were previously married, stigma may
have influenced a later average gestational age at first presen-
tation to clinic, as well as a lower likelihood of returning to
clinic and thus lower retesting rates. These data are corrobo-
rated by both the qualitative [19] and quantitative [20] litera-
ture. We also found that women newly diagnosed as being
HIV positive in ANC were significantly less likely to return to
clinic, a crucial group to focus on for the prevention of MTCT
and linkage to care for their own health. Women who were
known HIV positive were more likely to live further away from
the clinic, suggesting that stigma may have led them to seek
ANC away from their home, just as the literature indicates
that HIV stigma may lead individuals to seek general HIV care
far from home [21].
At the clinic level, factors unrelated to patient choices may
have been more influential in determining who among eligi-
ble returnees received retesting, as seen by the fact that
receipt of retesting was uncorrelated with demographic char-
acteristics. This also suggests that providers did not seem to
target certain profiles of women for retesting. In contrast,
year of LMP among eligible returnees was highly predictive
of getting retested, indicating that the dissemination of
retesting guidelines may have driven an increase in provider-
initiated testing. However, the fact that over 55% of women
still failed to get retested more than a year after guideline
dissemination (since women with LMPs in late 2013 deliv-
ered as late as October 2014) and that women continued to
fall through the cracks even though eligible at multiple visits
is concerning. Our prior study found that ability of providers
to remember when three months have elapsed since last
HIV test, clinic workload on day of patient visit, and availabil-
ity of adequate HIV test kits may impact whether providers
offer retesting [19].
This study has several strengths including the longitudinal
nature of the data which contained both demographic factors
and process/outcome measures. It also spanned the pregnancy
duration as well as the time prior to and after the dissemina-
tion of national repeat HIV testing guidelines. We were limited
by our inability to determine if women were retested at some
point during their pregnancy at other ANC facilities, although
we mitigated this likelihood by restricting the dataset to
women who had their first ANC visit at our site and thus
likely treated it as their primary care location. Similarly, we
were unable to determine if miscarriage was a reason for
non-return to ANC and were limited in our sociodemographic
variables to those which are routinely collected data. This was
also a single, semi-rural study site that was supported by
FACES and thus may not be representative of ANCs in other
areas. Finally, we were unable to assess whether HIV retesting
occurred at delivery and/or the postnatal periods, both of
which would include periods of continued high risk of HIV
acquisition and transmission. In spite of these limitations and
the age of the data at time of publication, we believe our find-
ings are applicable to many settings around the globe with
continuing high MTCT incidence. This is because we (a) pro-
vide a framework for conceptualizing missed opportunities
early in the HIV care cascade at the point of identifying preg-
nant women who are newly HIV positive despite having
recently tested HIV negative, and (b) highlight vulnerable
groups that may be at higher risk of incident HIV infection
and MTCT but fail to get retested.
5 | CONCLUSIONS
In conclusion, repeat HIV testing rates seem to have increased
in the post-guideline period, but improving late-pregnancy
detection of incident HIV infection may require community
mobilization and messaging surrounding earlier and more con-
sistent ANC visits, strategies that will also likely improve gen-
eral ANC, and the importance of HIV retesting. This is
particularly significant in the current era of initiating immedi-
ate, lifelong ART for all pregnant women who are living with
HIV. Further research should assess whether these findings
are applicable to other settings, determine the driving factors
for multiple missed opportunities for eligible women, and
assess clinic-level factors such time of day or day of week that
may impact provider-initiated testing. In addition, other stud-
ies should attempt to link ANC testing with delivery and post-
natal testing to assess retesting and ART initiation and
retention for women that acquired HIV in the perinatal
period.
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